Dogecoin Cash, Inc. Annual Report: A Plain-English Summary

This guide breaks down Dogecoin Cash, Inc.’s recent performance. My goal is to explain these filings clearly so you can decide if this company fits your investment goals.

1. What does this company actually do?

Despite the name, this company has nothing to do with Dogecoin cryptocurrency. They run a telemedicine business. Through their subsidiary, PrestoDoctor, they connect patients with doctors for medical cannabis evaluations in states where it is legal.

They also own subsidiaries like Dogecoin Treasury and Meme Coins, Inc., but these are just side projects for digital asset investments. As of December 31, 2025, the Dogecoin Treasury held less than $5,000 in digital assets. This represents less than 1% of the company’s total assets. The company is clear: their real business is telemedicine, not crypto.

2. How are they performing?

The company is struggling to grow. Revenue fell 8% in 2025, dropping from $803,260 to $739,000. They blame this on tougher competition, which lowered consultation fees and made it more expensive to find new customers.

They are, however, cutting costs. They reduced total operating expenses by 14% last year—from $1,495,000 to $1,285,000. They achieved this by cutting staff by 20%, reducing executive salaries by 15%, and slashing marketing spending by $120,000. Despite these cuts, the company lost $546,000 from operations in 2025, resulting in a loss of about $0.04 per share.

3. Financial health: The "Red Flags"

The company is in a tough spot. They ended 2025 with only $29,553 in cash. This is a very small safety net, covering less than one month of operating expenses.

The company is currently a "going concern." This means they are at risk of running out of money within three to six months. They will likely need to raise cash by selling more shares or taking on debt. If they issue more shares, they will reduce your ownership percentage. Based on their current spending, a cash raise could reduce your ownership stake by 20% to 30%.

4. Major risks to watch out for

• Name Confusion: The company is not affiliated with Dogecoin. If you are buying this stock as a crypto investment, you are mistaken.
• Regulatory Risk: Their business depends on state laws for medical cannabis and telemedicine. If these laws change, it could hurt their ability to operate in key markets like California and New York.
• Thinly Traded: With only 71 shareholders, the stock is "thinly traded." It is difficult to buy or sell shares without causing big price swings. Some days in 2025 saw fewer than 500 shares traded.
• Capital Needs: Because they are losing money, they constantly risk needing to raise cash. This usually hurts current shareholders through new share offerings or high-interest debt.

5. Future outlook

The company is focusing on PrestoDoctor. They aren't promising a "moonshot." They want steady, remote healthcare services and aim to break even by late 2026. However, given their shrinking revenue and low cash, the path to profitability is steep. Without new cash or a better marketing strategy, the company faces a high risk of running out of money within the next year.

---

Final Thought for Investors: Before considering an investment, ask yourself if you are comfortable with a company that is currently losing money, has very little cash on hand, and may need to dilute your shares to keep the lights on. This is a high-risk situation that requires careful consideration of the company's ability to turn its telemedicine business around.